HILLEMAN JERYL L 4

What Happened
Jeryl L. Hilleman, a director of Omada Health, was granted 1,544 restricted stock units (RSUs) on April 5, 2026. The RSUs were issued at $0.00 per share (total reported value $0) as an award under the company’s Non‑Employee Director Compensation Program, effectively representing the right to receive 1,544 shares of common stock when settled. This is an award of compensation rather than an open‑market purchase or sale.

Key Details

• Transaction date: 2026-04-05; Transaction type: Grant/Award (code A).
• Amount: 1,544 RSUs; Price per RSU: $0.00; Reported cash value: $0.
• Filing date: 2026-04-07 (Form 4 filed within the typical two‑business‑day window).
• Shares owned after transaction: Not specified in the filing.
• Footnote: RSUs granted pursuant to the Issuer’s Non‑Employee Director Compensation Program in lieu of retainer fees; each RSU entitles the holder to one share, with settlement either at a date selected by the reporting person or as provided by the Program.
• No exercise, sale, 10b5‑1 plan, or tax‑withholding disposition reported.

Context
Director RSU grants are common as routine compensation and do not necessarily signal a personal view on the stock’s near‑term prospects. RSUs convert to actual shares only upon settlement per the plan terms; until then they represent a promise of future shares. For retail investors, purchases or sales by insiders often provide clearer signals than routine compensation awards.